Fundraising Fox
/Companies
Sign in

Radiant Biotherapeutics

Founded 2020 · Quebec, Canada corporation · 31 employees on LinkedIn · 6 known investors

Find your way into Radiant Biotherapeutics

Sign up to see every warm intro you have to Radiant Biotherapeutics

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Radiant Biotherapeutics team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Radiant Biotherapeutics develops a platform of therapeutic molecules called Multabodies that engage multiple disease targets simultaneously within a single engineered protein to treat cancer and infectious diseases.

BiotechMedical Devices

Founders & leadership

AF
Arthur FratamicoExecutive
DGDeborah Geraghty, Ph.D.
Deborah Geraghty, Ph.D.President and Chief Executive Officer

Investors · 6

Toronto Innovation Acceleration Partnerslisted by Toronto Innovation Acceleration PartnersToronto
Amplitude Venture CapitalreportedMontreal

How we know: a partner's Signal profile · Not right? Tell us

Bill & Melinda Gates FoundationreportedSeattle

How we know: funding news · Not right? Tell us

Also in the syndicate · 2

Amplitude VenturesleadGates Foundationlead

Funding

SEC filings, press & company announcements

$34.3M disclosed across 1 of 2 rounds · 2024–2025

▶$34.3MraisedOct 2024 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Arthur FratamicoExecutive Officer, Promoter
Offering amount
$34.3M
Amount sold
$34.3M
Minimum investment
$500K
First sale
Aug 2024
Incorporated
Corporation, Quebec, Canada, 2020
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 3

Octant BioOctant is a therapeutics company that develops small molecule drugs to treat protein misfolding diseases. Using synthetic biology, high-throughput chemistry, and AI/ML, the company's Navigator platform studies how target proteins interact within living human cells to enable drug discovery for rare diseases and oncology.
Aro BiotherapeuticsAro Biotherapeutics develops tissue-targeted genetic medicines using a proprietary protein technology called Centyrins. The company builds a wholly-owned pipeline of Centyrin-based therapeutic candidates and partners with industry to enable tissue-specific targeting of therapeutics across a range of diseases.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies working in the same space as Radiant Biotherapeutics.

In the news

Amplitude Ventures, Gates Foundation lead Radiant Biotherapeutics’ $35-million USD Series A | BetaKitbetakit.com · Sep 2024Radiant Biotherapeutics Closes $35M Series A Financingfinsmes.com · Sep 2024

Frequently asked questions

What does Radiant Biotherapeutics do?
Radiant Biotherapeutics develops a platform of therapeutic molecules called Multabodies that engage multiple disease targets simultaneously within a single engineered protein to treat cancer and infectious diseases.
Who are Radiant Biotherapeutics's investors?
Radiant Biotherapeutics's investors include FACIT (Fight Against Cancer Innovation Trust), Toronto Innovation Acceleration Partners, Amplitude Venture Capital, Bill & Melinda Gates Foundation.
How much funding has Radiant Biotherapeutics raised?
Radiant Biotherapeutics has disclosed $34.3M raised across 1 of its 2 known rounds.